ClinicalTrials.gg
RecruitingNCT07675980Thy-α1 for RIFUpdated Nov 10, 2026

Thymosin-α1 for Recurrent Implantation Failure

A Phase 2/3 interventional study of Thymosin Alpha1 and Placebo Control in Recurrent Implantation Faliure, sponsored by Fakih IVF Fertility Center. Recruiting at 2 sites in United Arab Emirates. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Fakih IVF Fertility Center · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2026, registered Jun 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 10, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.

Read the detailed description

Despite significant advancements in assisted reproductive technologies (ART), recurrent implantation failure (RIF) remains a persistent challenge. Growing evidence implicates dysregulation of both local endometrial and systemic immune components in the pathophysiology of RIF.

This has led to increasing attention on immune dysregulation, including aberrant cytokine signaling, altered Th1/Th2 balance, heightened NK cell cytotoxicity, and impaired maternal-fetal tolerance as possible contributors. These immunological pathways are critical for embryo implantation and pregnancy continuation; their disruption can create an environment hostile to the developing conceptus.

Thymosin-α1 (Tα1) is a naturally occurring thymic peptide with immune-modulatory properties. It has been historically used in the management of chronic viral infections and certain cancers, where it demonstrated the ability to enhance T-cell function, rebalance cytokine networks, and improve immune resilience. Its safety profile in non-obstetric conditions is well established.

Although comprehensive safety evaluation of thymosin alpha in pregnant women has not yet been completed, emerging evidence from observational studies, case reports, and proposed clinical trials suggests that thymosin alpha is generally regarded as safe during pregnancy, with no reported adverse effects linked to its use to date. Specifically, a published case report documented successful pregnancy following thymosin alpha administration in a woman with recurrent implantation failure, noting an absence of fetal anomalies or significant adverse events and emphasizing the need for further prospective trials to establish broader safety and efficacy. Preliminary clinical protocols continue to monitor for adverse events in patients undergoing reproductive treatments, and none have identified safety concerns thus far.

Emerging reproductive data suggest a potential role of Tα1 in implantation and pregnancy maintenance. Observational work reported lower maternal Tα1 levels in women whose pregnancies ended in miscarriage compared with those that continued to viability; this effect was not seen with thymosin-β4, suggesting specificity. Mechanistically, Tα1 enhances T-cell maturation, restores Th1/Th2 balance, and promotes regulatory T-cell activity-processes central to maternal immune tolerance during early pregnancy.

Taken together, these findings highlight a gap: Tα1 has biological plausibility and early signals but no definitive RCT evidence. This underlines the need for a rigorous, placebo-controlled study of Tα1 in women with RIF. To our knowledge, this is the first randomized placebo-controlled study looking at Tα1 in RIF patients undergoing treatment using PGT-a tested embryos.

02

Conditions studied

  • Recurrent Implantation Faliure

Keywords

  • Thymosin
  • recurrent implantation failure
  • Thymosin alpha
  • PGT-a tested embryos
03

In context

Lead sponsor

Fakih IVF Fertility Center is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -Women 18-40 years
  2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos
  3. - Normal parental karyotypes
  4. - Normal uterine cavity on imaging
  5. - Negative antiphospholipid panel
  6. - Thyroid and prolactin controlled within local reference standards

Exclusion criteria

Exclusion Criteria:

  1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine)
  2. - Active
  3. -Active infection
  4. - Uncontrolled systemic disease
  5. - Current systemic
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    thymosin-α1

    Thymosin α1 in recurrent implantation failure patients

    Drug: Thymosin Alpha1

  • Placebo comparator
    Placebo

    Placebo arm.

    Other: Placebo Control

Interventions

  • DrugThymalfasinStudies of ThymalfasinThymalfasin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Start at luteal start in ART cycles and continue until 10+6 weeks' gestation.

  • OtherPlacebo Control

    Matching placebo injections on the same schedule and duration.

06

What researchers measure

Primary outcomes

  1. Live birth more than 24 weeks

    From date of randomization (luteal start ART) until end of intervention at 10 + 6 weeks and assessed up to live birth or miscarriage. Approximately 40 weeks.

    Time frame: Approximately 40 weeks

  2. Determine whether Tα1 increases live birth versus placebo.

    Live birth (singleton or multiple)

    Time frame: Approximately 40 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Graham JJ, Longhi MS, Heneghan MA. T helper cell immunity in pregnancy and influence on autoimmune disease progression. J Autoimmun. 2021 Jul;121:102651. doi: 10.1016/j.jaut.2021.102651. Epub 2021 May 18. PubMed 34020252 ↗
  • Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Fahem MMM, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020 Dec 15;9(5):67-78. doi: 10.5501/wjv.v9.i5.67. PubMed 33362999 ↗
  • Kaufmann RA, Welch RA, Mutchnick MG. Low periconceptional maternal serum thymosin alpha 1 levels are associated with blighted pregnancies. Am J Reprod Immunol. 1993 Apr;29(3):171-5. doi: 10.1111/j.1600-0897.1993.tb00583.x. PubMed 8373526 ↗
  • Robertson SA. Immune tolerance in pregnancy. Nat Rev Immunol. 2020;20:67-82
  • Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, Pierimarchi P, Serafino A, Mastino A, Bistoni F, Romani L, Rasi G. Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci. 2007 Sep;1112:225-34. doi: 10.1196/annals.1415.044. Epub 2007 Jun 28. PubMed 17600290 ↗
  • Lin, Y. et al. Maternal serum thymosin α1 and β4 levels in early pregnancy and risk of miscarriage. [Chinese study showing lower Tα1 in miscarriage]
  • Romani L, et al. Thymosin alpha-1: a safe and effective immune modulator in clinical practice. Expert Opin Biol Ther. 2016;16(5):691-707.
  • Goldstein AL, et al. Biological activities of thymosin alpha 1: clinical applications in disease modulation. Int Immunopharmacol. 2004;4(13):1781-1789.
  • Li J, et al. Case report: successful pregnancy following thymosin-α1 therapy in recurrent implantation failure. Pharm J. 2018.
  • Garofalo C, et al. Serum thymosin alpha-1 levels in early pregnancy and risk of miscarriage. Hum Reprod. 1992;7(9):1336-1339.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 30, 2026
StartActual
Feb 11, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 United Arab Emirates)
  • Fakih IVF Fertility Centre LLC · Abu Dhabi, United Arab Emirates
  • First IVF Fertility Centre · Abu Dhabi, United Arab Emirates
Show 1 removed
  • Fakih IVF · Abu Dhabi, United Arab Emirates
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    2 sites added, 1 site removed
    Show 2 added (2 United Arab Emirates)
    • Fakih IVF Fertility Centre LLC · Abu Dhabi, United Arab Emirates
    • First IVF Fertility Centre · Abu Dhabi, United Arab Emirates
    Show 1 removed
    • Fakih IVF · Abu Dhabi, United Arab Emirates
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07675980
Lead sponsor
Fakih IVF Fertility Center
Responsible party
Lamiya Mohiyiddeen (Research Director, Research Ethics Committee Chair, Fakih IVF Fertility Center) — Principal investigator
First posted
Jun 30, 2026
Start date
Feb 11, 2026
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Dr. Lamiya Mohiyiddeen, MD, FRCOG
Contact
lamiya.mohiyiddeen@fakihivf.com
+971543676002
Fatma Bathawab, PhD
Contact
fatma.bathawab@fakihivf.com
+971585707393
Dr. Michael Fakih, MD
principal investigator · Fakih IVF Abu Dhabi
Dr. Yasmin Sajjad, MD, FRCOG, DOWH
principal investigator · Fakih IVF Abu Dhabi
Dr. Lamiya Mohiyiddeen, MD, FRCOG
principal investigator · Fakih IVF Abu Dhabi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thymalfasin

Start the discussion